PMID- 30042500
OWN - NLM
STAT- MEDLINE
DCOM- 20190911
LR  - 20200225
IS  - 1476-5500 (Electronic)
IS  - 0929-1903 (Print)
IS  - 0929-1903 (Linking)
VI  - 26
IP  - 1-2
DP  - 2019 Feb
TI  - Efficient tumor transduction and antitumor efficacy in experimental human 
      osteosarcoma using retroviral replicating vectors.
PG  - 41-47
LID - 10.1038/s41417-018-0037-y [doi]
AB  - Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction 
      and enhanced therapeutic benefit in a wide variety of cancer models. Here, we 
      evaluated two different RRVs derived from amphotropic murine leukemia virus 
      (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular 
      receptors (PiT-2 and PiT-1, respectively) for viral entry, in human osteosarcoma 
      cells. Quantitative RT-PCR showed that low levels of expression of both receptors 
      were observed in normal and non-malignant cells. However, high PiT-2 (for AMLV) 
      and low PiT-1 (for GALV) expression was observed in most osteosarcoma cell lines. 
      Accordingly, AMLV expressing the green fluorescent protein gene infected and 
      replicated more efficiently than GALV in most osteosarcoma cell lines. 
      Furthermore, RRVs expressing the cytosine deaminase prodrug activator gene showed 
      differential cytotoxicity that correlated with the results of viral spread. 
      AMLV-RRV-mediated prodrug activator gene therapy achieved significant inhibition 
      of subcutaneous MG-63 tumor growth over GALV in nude mice. These data indicate 
      that AMLV vectors predominate over GALV in human osteosarcoma cells. Moreover, 
      our findings support the potential utility of the two RRVs in personalized cancer 
      virotherapy on the basis of receptor expression.
FAU - Kubo, Shuji
AU  - Kubo S
AD  - Unit of Molecular and Genetic Therapeutics, Institute for Advanced Medical 
      Sciences, Hyogo College of Medicine, Nishinomiya, Japan. s-kubo@hyo-med.ac.jp.
FAU - Takagi-Kimura, Misato
AU  - Takagi-Kimura M
AD  - Unit of Molecular and Genetic Therapeutics, Institute for Advanced Medical 
      Sciences, Hyogo College of Medicine, Nishinomiya, Japan.
FAU - Kasahara, Noriyuki
AU  - Kasahara N
AUID- ORCID: 0000-0002-9186-911X
AD  - Departments of Cell Biology and Pathology, Sylvester Comprehensive Cancer Center, 
      University of Miami, Miami, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180725
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
RN  - 0 (Prodrugs)
RN  - 0 (Receptors, Virus)
RN  - 0 (leukemia virus receptor, gibbon ape)
RN  - EC 3.5.4.1 (Cytosine Deaminase)
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/metabolism/*therapy
MH  - Cell Line, Tumor
MH  - Cytosine Deaminase
MH  - Female
MH  - Humans
MH  - *Leukemia Virus, Gibbon Ape
MH  - *Leukemia Virus, Murine
MH  - Mice
MH  - Mice, Nude
MH  - *Oncolytic Virotherapy
MH  - Osteosarcoma/metabolism/*therapy
MH  - Prodrugs
MH  - *Receptors, Virus
MH  - Treatment Outcome
MH  - Xenograft Model Antitumor Assays
PMC - PMC6760559
COIS- N.K. is a paid consultant to Tocagen Inc. This does not alter the authors' 
      adherence to all CGT policies on sharing data and materials. The remaining 
      authors declare that they have no conflict of interest.
EDAT- 2018/07/26 06:00
MHDA- 2019/09/12 06:00
PMCR- 2018/07/25
CRDT- 2018/07/26 06:00
PHST- 2018/04/01 00:00 [received]
PHST- 2018/05/24 00:00 [accepted]
PHST- 2018/05/12 00:00 [revised]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2019/09/12 06:00 [medline]
PHST- 2018/07/26 06:00 [entrez]
PHST- 2018/07/25 00:00 [pmc-release]
AID - 10.1038/s41417-018-0037-y [pii]
AID - 37 [pii]
AID - 10.1038/s41417-018-0037-y [doi]
PST - ppublish
SO  - Cancer Gene Ther. 2019 Feb;26(1-2):41-47. doi: 10.1038/s41417-018-0037-y. Epub 
      2018 Jul 25.